301230 泓博医药
已收盘 03-05 15:00:00
资讯
新帖
简况
股市必读：泓博医药(301230)股东户数2.12万户，较上期减少3.75%
证券之星 · 03-05 01:11
股市必读：泓博医药(301230)股东户数2.12万户，较上期减少3.75%
泓博医药：DiOrion平台作为公司自主研发的赋能药物研发的工具
证券之星 · 03-04 15:45
泓博医药：DiOrion平台作为公司自主研发的赋能药物研发的工具
泓博医药：截至2026年2月27日股东户数为21,199户
证券之星 · 03-04 15:45
泓博医药：截至2026年2月27日股东户数为21,199户
3月3日泓博医药跌7.56%，长城消费增值混合A基金重仓该股
证券之星 · 03-03 16:59
3月3日泓博医药跌7.56%，长城消费增值混合A基金重仓该股
泓博医药：截至2026年2月13日股东户数为22,025户
证券之星 · 02-26
泓博医药：截至2026年2月13日股东户数为22,025户
泓博医药（301230）披露关于更换保荐代表人的公告，2月25日股价上涨0.29%
证券之星 · 02-25
泓博医药（301230）披露关于更换保荐代表人的公告，2月25日股价上涨0.29%
泓博医药：截至2026年2月10日股东户数为22,411户
证券之星 · 02-12
泓博医药：截至2026年2月10日股东户数为22,411户
泓博医药(301230)1月30日股东户数2.46万户，较上期减少3.07%
证券之星 · 02-04
泓博医药(301230)1月30日股东户数2.46万户，较上期减少3.07%
泓博医药：截至2026年1月20日的股东户数为25,394户
证券之星 · 01-29
泓博医药：截至2026年1月20日的股东户数为25,394户
泓博医药2025年净利润预增超八成，一站式服务能力巩固竞争优势
中金财经 · 01-27
泓博医药2025年净利润预增超八成，一站式服务能力巩固竞争优势
泓博医药：截至2026年1月9日股东户数为15,496户
证券之星 · 01-27
泓博医药：截至2026年1月9日股东户数为15,496户
股市必读：泓博医药（301230）1月26日董秘有最新回复
证券之星 · 01-27
股市必读：泓博医药（301230）1月26日董秘有最新回复
泓博医药：DiOrion平台围绕药物早期研发的关键环节开展能力建设
证券之星 · 01-26
泓博医药：DiOrion平台围绕药物早期研发的关键环节开展能力建设
1月23日泓博医药涨6.67%，长城消费增值混合A基金重仓该股
证券之星 · 01-23
1月23日泓博医药涨6.67%，长城消费增值混合A基金重仓该股
1月15日泓博医药（301230）龙虎榜数据：游资上海溧阳路上榜
证券之星 · 01-15
1月15日泓博医药（301230）龙虎榜数据：游资上海溧阳路上榜
异动快报：泓博医药（301230）1月15日10点4分触及跌停板
中金财经 · 01-15
异动快报：泓博医药（301230）1月15日10点4分触及跌停板
泓博医药最新公告：现阶段DiOrion平台药物研发服务直接收入占公司整体营业收入的比重较小
证券之星 · 01-14
泓博医药最新公告：现阶段DiOrion平台药物研发服务直接收入占公司整体营业收入的比重较小
1月14日泓博医药（301230）龙虎榜数据：机构净买入532.9万元（3日）
证券之星 · 01-14
1月14日泓博医药（301230）龙虎榜数据：机构净买入532.9万元（3日）
1月14日泓博医药涨16.10%，长城消费增值混合A基金重仓该股
证券之星 · 01-14
1月14日泓博医药涨16.10%，长城消费增值混合A基金重仓该股
千亿出海+天价猴！CRO板块扎堆涨停，这波红利能吃到2026？
中金财经 · 01-13
千亿出海+天价猴！CRO板块扎堆涨停，这波红利能吃到2026？
加载更多
公司概况
公司名称：
上海泓博智源医药股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-11-01
主营业务：
上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。
发行价格：
40.00
{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":39.8,"timestamp":1772694198000,"preClose":38.34,"halted":0,"volume":5987687,"delay":0,"changeRate":0.0381,"floatShares":126000000,"shares":140000000,"eps":0.2622,"marketStatus":"已收盘","change":1.46,"latestTime":"03-05 15:00:00","open":39.13,"high":40.29,"low":38.66,"amount":236000000,"amplitude":0.0425,"askPrice":39.82,"askSize":27,"bidPrice":39.8,"bidSize":284,"shortable":0,"etf":0,"ttmEps":0.2622,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":38.34,"symbolType":"stock","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":42.17,"lowLimit":34.51,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":139586605,"isCdr":false,"pbRate":5.22,"roa":"--","peRate":151.792525,"roe":"3.3%","epsLYR":0.12,"committee":0.685185,"marketValue":5556000000,"turnoverRate":0.0477,"status":0,"floatMarketCap":5000000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2617557464","title":"股市必读：泓博医药(301230)股东户数2.12万户，较上期减少3.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557464","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617557464?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:11","pubTimestamp":1772644271,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，泓博医药报收于38.34元，下跌2.59%，换手率4.09%，成交量5.14万手，成交额1.99亿元。股本股东变化股东户数变动近日泓博医药披露，截至2026年2月27日公司股东户数为2.12万户，较2月13日减少826.0户，减幅为3.75%。户均持股数量由上期的6338.0股增加至6585.0股，户均持股市值为29.35万元。根据中登公司下发的股东名册，截至2026年2月27日（交易日），公司的股东户数为21,199户，目前公司股东结构保持稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2616582729","title":"泓博医药：DiOrion平台作为公司自主研发的赋能药物研发的工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2616582729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616582729?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:45","pubTimestamp":1772610325,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：DiOrion平台2026年新增临床/IND项目数量与客户拓展情况？DiOrion平台作为公司自主研发的赋能药物研发的工具，目前仍在稳步迭代升级中，致力于帮助客户加速早期药物发现进程。公司目前正在编制2025年年度报告，相关经营数据及业务进展将按照监管要求在定期报告中统一披露，敬请关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400023127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2616958271","title":"泓博医药：截至2026年2月27日股东户数为21,199户","url":"https://stock-news.laohu8.com/highlight/detail?id=2616958271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616958271?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:45","pubTimestamp":1772610316,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截至最新股东户数是多少？公司目前股东结构是否稳定？是否有应披露而未披露的重大信息？谢谢。泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年2月27日（交易日），公司的股东户数为21,199户，目前公司股东结构保持稳定。公司严格按照法律法规履行信息披露义务，不存在应披露而未披露的重大信息。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400023100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2616231011","title":"3月3日泓博医药跌7.56%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616231011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616231011?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:59","pubTimestamp":1772528348,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日泓博医药跌7.56%，收盘报39.36元，换手率6.18%，成交量7.76万手，成交额3.16亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.2171，较上一交易日下跌1.96%，近一年上涨6.74%。该公募基金现任基金经理为龙宇飞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2614090303","title":"泓博医药：截至2026年2月13日股东户数为22,025户","url":"https://stock-news.laohu8.com/highlight/detail?id=2614090303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614090303?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:45","pubTimestamp":1772091924,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问最新一期公司的股东人数是多少？泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年2月13日（交易日），公司的股东户数为22,025户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600019073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2614033532","title":"泓博医药（301230）披露关于更换保荐代表人的公告，2月25日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614033532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614033532?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:17","pubTimestamp":1772029034,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，泓博医药报收于44.58元，较前一交易日上涨0.29%，最新总市值为62.23亿元。该股当日开盘44.31元，最高44.79元，最低43.58元，成交额达1.91亿元，换手率为3.43%。泓博医药于近日披露《关于更换保荐代表人的公告》。公告显示，公司收到中信证券《关于更换保荐代表人的函》，因原保荐代表人王琦先生工作调整，不再担任持续督导保荐代表人，中信证券委派元彬龙先生接替其工作。公司持续督导期至中国证监会和深交所规定结束为止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500037991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2610995339","title":"泓博医药：截至2026年2月10日股东户数为22,411户","url":"https://stock-news.laohu8.com/highlight/detail?id=2610995339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610995339?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:03","pubTimestamp":1770858190,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至2026年2月10日收盘，公司的股东户数是多少？谢谢。泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年2月10日（交易日），公司的股东户数为22,411户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200006144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2608354259","title":"泓博医药(301230)1月30日股东户数2.46万户，较上期减少3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608354259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608354259?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:30","pubTimestamp":1770197441,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泓博医药披露，截至2026年1月30日公司股东户数为2.46万户，较1月20日减少780.0户，减幅为3.07%。在医疗服务行业个股中，泓博医药股东户数低于行业平均水平，截至1月30日，医疗服务行业平均股东户数为4.63万户。从股价来看，2026年1月20日至2026年1月30日，泓博医药区间涨幅为1.82%，在此期间股东户数减少780.0户，减幅为3.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400029699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2607072228","title":"泓博医药：截至2026年1月20日的股东户数为25,394户","url":"https://stock-news.laohu8.com/highlight/detail?id=2607072228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607072228?lang=zh_cn&edition=full","pubTime":"2026-01-29 08:36","pubTimestamp":1769646972,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：你好：请问贵公司截止2026年1月20日的股东户数，谢谢泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年1月20日（交易日），公司的股东户数为25,394户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900006677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2606042482","title":"泓博医药2025年净利润预增超八成，一站式服务能力巩固竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2606042482","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606042482?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:57","pubTimestamp":1769504268,"startTime":"0","endTime":"0","summary":"中访网数据 上海泓博智源医药股份有限公司于2026年1月27日发布2025年度业绩预告。预告显示，公司预计2025年度归属于上市公司股东的净利润为3,120万元至3,810万元，较上年同期的1,708.32万元增长82.64%至123.03%；预计扣除非经常性损益后的净利润为2,090万元至2,560万元，同比大幅增长321.59%至416.40%。 公司提示，本次业绩预告数据为财务部门初步测算结果，未经会计师事务所审计，具体财务数据以公司正式披露的2025年年度报告为准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260127/31975966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301230"],"gpt_icon":0},{"id":"2606220297","title":"泓博医药：截至2026年1月9日股东户数为15,496户","url":"https://stock-news.laohu8.com/highlight/detail?id=2606220297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606220297?lang=zh_cn&edition=full","pubTime":"2026-01-27 08:43","pubTimestamp":1769474589,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)01月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司一月十号股东数量多少，谢谢泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年1月9日（交易日），公司的股东户数为15,496户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700007819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2606247549","title":"股市必读：泓博医药（301230）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606247549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606247549?lang=zh_cn&edition=full","pubTime":"2026-01-27 01:08","pubTimestamp":1769447296,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，泓博医药报收于50.2元，上涨1.64%，换手率14.41%，成交量18.1万手，成交额9.28亿元。董秘最新回复投资者： AI4S是AI在产业层面的重要落地实践，制药是重要的应用领域。截至2025年8月，公司DiOrion平台已累计为95个新药项目提供技术支持，其中7个项目已进入临床实验阶段，平台服务客户总数达45家，涵盖多个治疗领域。交易信息汇总资金流向1月26日主力资金净流入3280.75万元；游资资金净流入5224.03万元；散户资金净流出8504.78万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2606182622","title":"泓博医药：DiOrion平台围绕药物早期研发的关键环节开展能力建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2606182622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606182622?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:39","pubTimestamp":1769416749,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药01月26日在投资者关系平台上答复投资者关心的问题。投资者提问：AI4S是AI在产业层面的重要落地实践，制药是重要的应用领域。公司是否开展AI4S业务建立AI制药开发平台，推动公司制药业务的加速发展？公司的DiOrion平台围绕药物早期研发的关键环节开展能力建设，包括分子设计、虚拟筛选、成药性评估、专利风险分析等方向的模块化能力建设。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600018199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2605493422","title":"1月23日泓博医药涨6.67%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2605493422","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605493422?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:46","pubTimestamp":1769154405,"startTime":"0","endTime":"0","summary":"证券之星消息，1月23日泓博医药涨6.67%，收盘报49.39元，换手率11.93%，成交量14.99万手，成交额7.3亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.2685，较上一交易日下跌0.38%，近一年上涨34.59%。该公募基金现任基金经理为龙宇飞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300020063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2603033356","title":"1月15日泓博医药（301230）龙虎榜数据：游资上海溧阳路上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2603033356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603033356?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:38","pubTimestamp":1768469900,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月15日公布的交易公开信息显示，泓博医药因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第3次上榜。截至2026年1月15日收盘，泓博医药报收于52.61元，下跌20.0%，跌停，换手率13.08%，成交量16.43万手，成交额8.88亿元。上海溧阳路等知名游资榜上有名。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2603210146","title":"异动快报：泓博医药（301230）1月15日10点4分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603210146","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603210146?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:13","pubTimestamp":1768443212,"startTime":"0","endTime":"0","summary":"证券之星1月15日盘中消息，10点4分泓博医药(301230)触及跌停板。其所属行业医疗服务目前下跌。领涨股为通策医疗。该股为合成生物，化学原料药，流感概念热股。1月14日的资金流向数据方面，主力资金净流出1.19亿元，占总成交额5.03%，游资资金净流出1559.23万元，占总成交额0.66%，散户资金净流入1.34亿元，占总成交额5.69%。近5日资金流向一览见下表： 泓博医药主要指标及行业内排名如下： 为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/15/20260115377986.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/15/20260115377986.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260115/31944241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2603138326","title":"泓博医药最新公告：现阶段DiOrion平台药物研发服务直接收入占公司整体营业收入的比重较小","url":"https://stock-news.laohu8.com/highlight/detail?id=2603138326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603138326?lang=zh_cn&edition=full","pubTime":"2026-01-14 20:00","pubTimestamp":1768392018,"startTime":"0","endTime":"0","summary":"泓博医药(301230.SZ)发布股票交易异常波动及股票交易严重异常波动公告称，现阶段公司DiOrion平台药物研发服务的直接收入占公司整体营业收入的比重较小，对公司整体经营情况不构成重大影响。经自查，公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400037092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230"],"gpt_icon":0},{"id":"2603691873","title":"1月14日泓博医药（301230）龙虎榜数据：机构净买入532.9万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2603691873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603691873?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:31","pubTimestamp":1768383101,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月14日公布的交易公开信息显示，泓博医药因连续三个交易日内，涨幅偏离值累计达到30%的证券，严重异常期间日收盘价格涨幅偏离值累计达到100%的证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年1月14日收盘，泓博医药报收于65.76元，上涨16.1%，换手率31.33%，成交量39.35万手，成交额23.56亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入532.9万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400029670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2603698601","title":"1月14日泓博医药涨16.10%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603698601","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603698601?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:41","pubTimestamp":1768376500,"startTime":"0","endTime":"0","summary":"证券之星消息，1月14日泓博医药涨16.10%创60日新高，收盘报65.76元，换手率31.33%，成交量39.35万手，成交额23.56亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为5.16亿元，最新净值1.374，较上一交易日上涨1.24%，近一年上涨50.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2603750260","title":"千亿出海+天价猴！CRO板块扎堆涨停，这波红利能吃到2026？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603750260","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603750260?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:30","pubTimestamp":1768296601,"startTime":"0","endTime":"0","summary":"据悉，2025年国内创新药BD出海金额突破1000亿美元，2026年预期加速，CRO企业作为研发外包核心服务商直接受益于订单放量。另外，2025年12月，广东、广西等地猴场实验猴已订至2026年上半年，供不应求局面持续，推动CRO企业战略资源溢价。一猴难求除了创新药出海带来的订单红利，实验猴资源的稀缺性进一步推升了CRO企业的战略价值。机构看好企业发展前景机构普遍看好CRO板块2026年的发展前景。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/13/20260113553813.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/13/20260113553813.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260113/31938136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06978","301257","BK1161","301230","BK0236","301060","BK0146","BK0216","BK0028","BK0042","BK1574","BK0114","300404","BK0186","BK0070","300244","BK0197","688137","301333"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772743100791,"stockEarnings":[{"period":"1week","weight":-0.1},{"period":"1month","weight":-0.1831},{"period":"3month","weight":0.3184},{"period":"6month","weight":0.0548},{"period":"1year","weight":0.1227},{"period":"ytd","weight":0.3353}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"21199人(较上一季度减少3.75%)","perCapita":"5925股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"13958万元","survey":" 上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}